via Reflexology-Bio Energy Therapy-Holistic Massage-Galway
In a long-term collaboration between researchers and industry, an exciting first step has been made in the creation of a new generation of medicines for auto-immune diseases using one of our body’s own anti-inflammatory off-switch molecules.
The immune system produces many highly potent anti-inflammatory molecules, but they are often fragile, short-lived, and lack drug-like properties. Interleukin-37 is one such molecule produced by the body to turn off inflammation.
Together with partner F. Hoffmann-La Roche (Roche), the multidisciplinary research team from Hudson Institute of Medical Research, Monash University Biomedicine Discovery Institute (BDI) and Monash University’s Department of Paediatrics has harnessed their Fc-fusion platform to engineer the next generation of Interleukin-37, one that retains anti-inflammatory potency, is highly stable and has an excellent therapeutic likeness.
The findings from the research collaboration have now been published in Cell Chemical Biology.
Engineering the next generation of anti-inflammatories
Associate Professor Claudia Nold at the Hudson Institute of Medical Research, one of the lead scientists, said: “Working in the field of inflammation, we were delighted to partner with Roche, a Swiss pioneer in healthcare since 1896. Our collaboration between academia, clinicians and industry partners such as Roche enabled us to leverage our combined expertise and solve biomedical questions to get a step closer in developing innovative medicines for patients suffering from inflammatory diseases.”
A little bit of inflammation can be a good thing and is often the body’s immune system doing its job. However, when inflammation persists, or the immune system starts attacking the body’s own cells, this can lead to disease. This research aims to create a new generation of medicines for auto-immune diseases.
Diseases characterised by too much inflammation
Another of the study’s lead authors, Dr Andrew Ellisdon from the Monash BDI, says many human diseases, including autoimmune conditions such as arthritis, lupus or inflammatory bowel disease, are characterised by too much inflammation.
Dr Ellisdon says there has been a gap in producing new generations of potent anti-inflammatory therapeutics for these anti-inflammatory conditions.
“The past five years have been a remarkable opportunity to collaborate and learn from Roche, a global leader in the engineering and development of biologics. Because of the data from this study, we now know how to make more stable and medicine-like versions of the body’s own anti-inflammatory off-switches,” he said.
“This study builds a solid platform to test IL-37-based Fc-fusion variants in a range of preclinical models of inflammatory and autoimmune disease. We anticipate that many of the steps undertaken in this Fc-engineering platform will be broadly applicable to other challenging and unstable biologics.”
Professor Marcel Nold, a Professor of Paediatric Immunology at Monash University and a consultant Neonatal Paediatrician at Monash Children’s Hospital, said “It is a clinician scientist’s ultimate goal to be part of research that can be translated into future patient treatments.”
Original Article: Flicking the inflammation off-switch
More from: Hudson Institute of Medical Research | Monash University
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Anti-inflammatory off-switch molecules
- Tsetse fly protein provides anticoagulant with its own on-off switch
A completely novel way to develop 'surpamolecules' for drug discovery could have application in immunotherapy as well as this breakthrough design for an anticoagulant with on-demand reversibility.
- Study finds network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease
A simple blood test could allow doctors to determine whether a person may be at higher risk for stroke or cognitive decline during their lifetime, according to a new UCLA Health study.
- New Technique to Identify Anti-Aging Molecules
“The goal of our research is to spur academic-industry collaborations to help bring effective anti-aging therapeutics to the clinics.” ...
- Top 8 Best Anti-Inflammatory Supplements in 2024
The focus of this article is to highlight the top anti-inflammatory supplement. There are various types of anti-inflammatory supplements available, including turmeric, omega-3 fatty acids ...
- 7 Anti-Inflammatory Dinner Ideas (That Also Support Your Gut Health)
Here's how to make easy, nourishing, anti-inflammatory dinners ... “Our immune system sends out inflammatory cells to help kill off any bacteria, infection, or viruses that have entered the ...
Go deeper with Google Headlines on:
Anti-inflammatory off-switch molecules
[google_news title=”” keyword=”anti-inflammatory off-switch molecules” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Inflammation switch
- Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar
In Canada, a study on inflammatory bowel disease (IBD) patients switching to infliximab or adalimumab biosimilars found no change in clinical remission or antidrug antibodies after 24 weeks, but 13% ...
- Injured Braves reliever Pierce Johnson is progressing well
On Friday, Johnson was scheduled to throw off the bullpen mound at low intensity. Johnson, who isn’t eligible to return from the injured list until May 16, is progressing well. “Everything’s looking ...
- Why some health experts are making the switch from coffee to cocoa powder
Interest in cocoa powder as a coffee alternative is on the rise. Should you make the switch? Here's what nutrition experts want you to know.
- The mysterious syndrome that strikes ‘like the flick of a switch’ and turns children as young as 3 ‘psychotic overnight
The rare and mysterious neuropsychiatric condition can strike children as young as three following a strep A infectionCredit: Alamy His concerned mum Megan checked on him that night and was shocked at ...
- A sugar switch for anti-inflammatory antibodies
The finding that antibody sialylation can suppress inflammation provides new opportunities for drug development. Figure 1: The IgG molecule comprises two light (L) and two heavy (H) chains in ...
Go deeper with Google Headlines on:
Inflammation switch
[google_news title=”” keyword=”inflammation switch” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]